BC Advantage Funds

BC Advantage Funds invests in early-stage life science, technology, and clean tech companies.

Business Model: B2B

Revenue: $14.5M

Employees: 2-10

Rankings

Detailed BC Advantage Funds Information

Geographic Data

BC Advantage Funds headquarters map

Address: 221 Esplanade W 410

City: North Vancouver

State: british columbia

Zip: V7M 3J3

Country: CA

Financial Info

Stage:

Raised Last:

$0

Raised Total:

$0

Metrics

0Website Global Rank

0Website Monthly Traffic

Twitter Followers

Description

BC Advantage Funds is a venture capital firm that caters to early stage life science, technology, and clean tech companies. In 2006, the company received the Canadian Venture Capital Association &s;Deal of the Year&s; award for achieving the highest realized return on a single investment (23.4X return on our investment in Aspreva Pharmaceuticals) of any venture capital firm in Canada. Furthermore, in the three years prior to its redemption (2006,2007, 2008), its Advantage Life Science Fund I provided the highest 5-year returns of any retail fund in Canada (Source: GlobeFund). Advantage most recent venture capital fund, the Advantage Structured Fund, was primarily raised and invested in the robust pre financial-crisis environment of 2004 – 2007. Since the financial crisis and recession of 2008 – 2009, we have had the challenging task of growing these businesses, keeping them financed despite difficult capital markets, and seeking profitable exits from the investments in a post financial-crisis environment characterized by few (if any) initial public offerings (IPOs), depressed activity in merger and acquisition (M&a;A) markets, and weakened valuations for emerging technology companies. In July, 2016, Advantage announced that its Board of Directors had concluded a review of strategic alternatives and determined that a liquidation and dissolution of the Company is the best alternative for maximizing shareholder value. The Board subsequently called an annual and special meeting of shareholders of the Company to approve a number of items, including the voluntary dissolution of the Company under Division 2 of Part 10 of the Business Corporations Act (British Columbia), the settlement of all of the assets of the Company on the Liquidation Trustee (as defined in the information circular in respect of the Meeting) on trust that the Trustee assume and pay all of the liabilities of the Company, and distribute all remaining assets of the Trust rateably to the shareholders of record. The Dissolution Resolution was approved by way of an ordinary and special resolution passed by a majority and at least two-thirds, respectively, of the votes cast by the Company’s shareholders the Meeting.

Contact Phone:

Contact Email:

Announced Date Company Transaction Money Raised
9/2010 Microvisk Technologies Series A 3.9M
6/2008 Inimex Pharmaceuticals Series B 22M
4/2006 GaleForce Solutions Series B 2.1M
12/2007 Zeugma Systems Series B 20M
3/2009 Zeugma Systems Series C 8.8M
6/2007 Contigo Systems Series B 3M
4/2008 Mobidia Technology Venture Round 9.3M
1/2007 Mobidia Technology Series A 0
7/2005 Mobidia Technology Series A 6M
7/2005 MetroBridge Networks Series B -
11/2014 Redlen Technologies Venture Round 2M
2/2010 Redlen Technologies Venture Round 7.8M
1/2010 Microvisk Technologies Venture Round 3.2M
5/2008 NPS Venture Round 9.7M
6/2007 Aquinox Pharmaceuticals Series A 14.5M
11/2014 Redlen Technologies Venture Round 0
2/2010 Redlen Technologies Venture Round 0
1/2010 Microvisk Technologies Venture Round 0
3/2009 Zeugma Systems Series C 0
6/2008 Inimex Pharmaceuticals Series B 0
5/2008 NPS Venture Round 0
4/2008 Mobidia Technology Venture Round 0
12/2007 Zeugma Systems Series B 0
6/2007 Aquinox Pharmaceuticals Series A 0
6/2007 Contigo Systems Series B 0

Startup Industries

Startup Locations

Portfolio Current Status

Portfolio Employee Count

Name Price
Name Size Announced Date

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research